Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Bromfenac Ophthalmic Solution, 0.09%, to market a generic equivalent of Bromday Ophthalmic Solution, 0.09%, of Bausch & Lomb Inc. This product will be manufactured at Lupin’s Pithampur facility in India. Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of $11 million in the U.S. (IQVIA MAT June 2023).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
